Search

Your search keyword '"Malhotra, Anshu"' showing total 4 results
Start Over Author "Malhotra, Anshu" Publisher mdpi
4 results on '"Malhotra, Anshu"'

1. Modernity and Caste in Khatri and High-Caste Men's Auto/Biographies.

Author

Malhotra, Anshu

Subjects
*CASTE, *MIDDLE class, *NINETEENTH century, *TWENTIETH century, *SCIENTISM, *BIOGRAPHY (Literary form)
Abstract

This paper studies the auto/biographies of high-caste middle-class Punjabi Khatri men, and those of cognate castes like Arora and Baniya, written in the first half of the twentieth century: men who were born in the second half of the nineteenth century or early twentieth century. While the discourse on caste under the colonial regime exploded, there was also an embarrassment about caste, or re-thinking its place in society among the upper-caste groups who invested in ideas of progress, improvement and scientism. It is argued that caste was referenced in the memoirs, life stories and self-reflexive writing when these men spoke of their familial backgrounds and admired the deep religiosity and devotionalism of their fathers even though some paternal practices were incongruent with the reformism of the sons. Caste is also in play when one traces the advantages of literacy, education, professional accomplishments, mobility, and reformist activities of men who came to have an important presence in public life. A number of these men had similar life trajectories, indicative of how some aspects of colonial educational and administrative structures could be utilized by them. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. Liposome-Imipramine Blue Inhibits Sonic Hedgehog Medulloblastoma In Vivo

Author

MacDonald, Tobey J., Liu, Jingbo, Yu, Bing, Malhotra, Anshu, Munson, Jennifer M., Park, Jaekeun C., Wang, Kenty, Fei, Baowei, Bellamkonda, Ravi, Arbiser, Jack, MacDonald, Tobey J., Liu, Jingbo, Yu, Bing, Malhotra, Anshu, Munson, Jennifer M., Park, Jaekeun C., Wang, Kenty, Fei, Baowei, Bellamkonda, Ravi, and Arbiser, Jack

Abstract

Sonic hedgehog subtype of medulloblastoma (SHH MB) with metastasis or specific clinical or molecular alteration shas a poor prognosis and current therapy results in long-term cognitive impairment in the majority of survivors. Thus, a great need exists for new targeted therapeutic approaches to more effectively treat SHH MB in children. Imipramine blue (IB), a novel molecule with anti-tumor properties, inhibits the NADPH oxidase (NOX) family of enzymes, which are critical for SHH MB survival and treatment resistance. In this study, IB was encapsulated within a liposome to form a liposomal nanoparticle, Liposome-IB (Lipo-IB). This complex has the ability to cross the blood–brain barrier and be preferentially taken up by tumor cells within the brain. We demonstrated in vitro that Lipo-IB treatment caused a dose-dependent decrease in SHH MB cell viability and migration. Short-term administration of single agent Lipo-IB treatment of SHH MB in vivo significantly inhibited tumor growth, reduced the tumor volume, including a complete tumor response, and improved survival compared to control treated mice, without any observable toxicity. We conclude that Lipo-IB is a potential novel nanoparticle-based therapeutic for the treatment of SHH MB that warrants further preclinical safety and efficacy testing for development towards clinical investigation.

Published
2021
Full Text
View/download PDF

3. Liposome-Imipramine Blue Inhibits Sonic Hedgehog Medulloblastoma In Vivo

Author

Fralin Biomedical Research Institute, MacDonald, Tobey J., Liu, Jingbo, Yu, Bing, Malhotra, Anshu, Munson, Jennifer M., Park, Jaekeun C., Wang, Kenty, Fei, Baowei, Bellamkonda, Ravi, Arbiser, Jack, Fralin Biomedical Research Institute, MacDonald, Tobey J., Liu, Jingbo, Yu, Bing, Malhotra, Anshu, Munson, Jennifer M., Park, Jaekeun C., Wang, Kenty, Fei, Baowei, Bellamkonda, Ravi, and Arbiser, Jack

Abstract

Sonic hedgehog subtype of medulloblastoma (SHH MB) with metastasis or specific clinical or molecular alteration shas a poor prognosis and current therapy results in long-term cognitive impairment in the majority of survivors. Thus, a great need exists for new targeted therapeutic approaches to more effectively treat SHH MB in children. Imipramine blue (IB), a novel molecule with anti-tumor properties, inhibits the NADPH oxidase (NOX) family of enzymes, which are critical for SHH MB survival and treatment resistance. In this study, IB was encapsulated within a liposome to form a liposomal nanoparticle, Liposome-IB (Lipo-IB). This complex has the ability to cross the blood–brain barrier and be preferentially taken up by tumor cells within the brain. We demonstrated in vitro that Lipo-IB treatment caused a dose-dependent decrease in SHH MB cell viability and migration. Short-term administration of single agent Lipo-IB treatment of SHH MB in vivo significantly inhibited tumor growth, reduced the tumor volume, including a complete tumor response, and improved survival compared to control treated mice, without any observable toxicity. We conclude that Lipo-IB is a potential novel nanoparticle-based therapeutic for the treatment of SHH MB that warrants further preclinical safety and efficacy testing for development towards clinical investigation.

Published
2021

4. Liposome-Imipramine Blue Inhibits Sonic Hedgehog Medulloblastoma In Vivo.

Author

MacDonald TJ, Liu J, Yu B, Malhotra A, Munson J, Park JC, Wang K, Fei B, Bellamkonda R, and Arbiser J

Abstract

Sonic hedgehog subtype of medulloblastoma (SHH MB) with metastasis or specific clinical or molecular alteration shas a poor prognosis and current therapy results in long-term cognitive impairment in the majority of survivors. Thus, a great need exists for new targeted therapeutic approaches to more effectively treat SHH MB in children. Imipramine blue (IB), a novel molecule with anti-tumor properties, inhibits the NADPH oxidase (NOX) family of enzymes, which are critical for SHH MB survival and treatment resistance. In this study, IB was encapsulated within a liposome to form a liposomal nanoparticle, Liposome-IB (Lipo-IB). This complex has the ability to cross the blood-brain barrier and be preferentially taken up by tumor cells within the brain. We demonstrated in vitro that Lipo-IB treatment caused a dose-dependent decrease in SHH MB cell viability and migration. Short-term administration of single agent Lipo-IB treatment of SHH MB in vivo significantly inhibited tumor growth, reduced the tumor volume, including a complete tumor response, and improved survival compared to control treated mice, without any observable toxicity. We conclude that Lipo-IB is a potential novel nanoparticle-based therapeutic for the treatment of SHH MB that warrants further preclinical safety and efficacy testing for development towards clinical investigation.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results